Kytopen, an MIT spin-out, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells and enhancing the cell’s biology. The Flowfect® platform accelerates therapies from the bench to clinical through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopen’s goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to many more patients. For more information, visit: www.kytopen.com
Location: United States
Employees: 11-50
Total raised: $33.6M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 29.01.2023 | Bantam Gro... | bantamgrou... |
| 24.08.2022 | MassVentur... | mass-ventu... |
| - | Engine Ven... | enginevent... |
| - | TBD Angels | tbdangels.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.09.2021 | Series A | $30M | - |
| 29.05.2019 | Seed | $3.6M | - |
Mentions in press and media 19
| Date | Title | Description |
| 07.04.2026 | Kytopen Closes Series B Funding | Kytopen Corp., a Cambridge, MA-based company which specializes in non-viral, continuous flow cellular engineering solutions, raised an undisclosed amount in Series B funding. The round was led by Telegraph Hill Partners, with participation ... |
| 07.04.2026 | Trent AI Raises $13M in Seed Funding | Trent AI, a London, UK-based agentic security company, raised $13M in Seed funding. The round was led by LocalGlobe and Cambridge Innovation Capital, with participation from leaders at OpenAI, Spotify, Databricks, AWS and others, The compan... |
| 08.04.2024 | Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer | CAMBRIDGE, Mass. and DENVER, April 8, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, today announced the appointment of Kevin Gutshall as Chief Co... |
| 26.03.2024 | Kytopen Announces Launch of Technology Access Program Supported by an Expanded Applications Team | CAMBRIDGE, Mass. and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Prog... |
| 13.01.2023 | Slone Partners Places Paul Wotton, Ph.D. as Chair of Board of Directors at Kytopen | “Paul Wotton is an extremely accomplished and talented leader and visionary in biotech, advanced cell technology, and biopharmaceutical research, discovery, and marketing,” said Slone Partners CEO Leslie Loveless. SOUTH RIDING, Va. (PRWEB) ... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content To retain talent, employers can't skip on fertility benefits From Maven Clinic To th... |
| 28.09.2021 | MIT cell-engineering spinout nets $30M for mass manufacturing platform | One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins, that genetic information is necessary to bend the cell toward becoming a real therapeutic. So far, t... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Why the Electricity 4.0 moment is here From Schneider Electric To the chagrin of man... |
| 28.09.2021 | MIT cell-engineering spinout nets $30M for mass manufacturing platform | One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins, that genetic information is necessary to bend the cell toward becoming a real therapeutic. Originall... |
| 28.09.2021 | Kytopen Raises $30M in Series A Funding | Kytopen Corp., a Cambridge, Mass.-based biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, raised $30m in Series A funding. The round was led by Northpond Ventures, with participation from cu... |
Show more